ストックスクリーナーアプリを入手
1.86
0.53%
-0.01
プレマーケット:
1.86
前日終値:
$1.87
開ける：
$1.88
24時間の取引高:
267.45K
Relative Volume:
0.42
時価総額：
$51.35M
収益：
$80.97M
当期純損益:
$-78.31M
株価収益率:
-0.1678
EPS:
-11.0849
ネットキャッシュフロー:
$-129.56M
1週間 パフォーマンス:
-1.85%
1か月 パフォーマンス:
+8.14%
6か月 パフォーマンス:
-13.49%
1年 パフォーマンス:
-2.11%
1日の値動き範囲:
$1.82
$1.92
1週間の範囲:
$1.82
$1.97
52週間の値動き範囲:
$1.355
$2.89
Fortress Biotech Inc Stock (FBIO) Company Profile
名前
Fortress Biotech Inc
セクター
電話
781-652-4500
住所
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
FBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.86 | 51.35M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-15 | 再開されました | ROTH MKM | Buy |
| 2022-08-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-02 | 開始されました | The Benchmark Company | Buy |
| 2019-12-18 | 開始されました | B. Riley FBR | Buy |
| 2018-02-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
| 2017-03-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-10-03 | 開始されました | ROTH Capital | Buy |
すべてを表示
Fortress Biotech Inc (FBIO) 最新ニュース
Fortress Biotech, Inc. (NASDAQ:FBIO) Sees Large Increase in Short Interest - MarketBeat
Fortress Biotech (NASDAQ: FBIO) Receives Notification of Extended FDA Target Action Date for CUTX-101 - Defense World
FDA extends review of Fortress Biotech's CUTX-101 drug - MSN
FDA extends review of Fortress Biotech's CUTX-101 drug By Investing.com - Investing.com South Africa
How the (FBIOP) price action is used to our Advantage - Stock Traders Daily
Mustang Bio announces 1-for-50 reverse stock split By Investing.com - Investing.com Canada
Mustang Bio announces 1-for-50 reverse stock split - Investing.com India
Geode Capital Management LLC Boosts Holdings in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Insiders Enjoy US$156k Return After Buying Fortress Biotech Stock - Simply Wall St
Drug to treat rare pediatric disease accepted for FDA review - The Business Journals
Fortress Biotech’s Subsidiary Cyprium Therapeutics Receives FDA Acceptance for CUTX-101 NDA Review - Defense World
Fortress Biotech subsidiary's drug application accepted by FDA By Investing.com - Investing.com South Africa
Fortress Biotech subsidiary's drug application accepted by FDA - Investing.com
Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease - The Eastern Progress Online
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA - GlobeNewswire
Fortress Biotech (FBIO) and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 - StreetInsider.com
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average – What’s Next? - Defense World
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
When the Price of (FBIOP) Talks, People Listen - Stock Traders Daily
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Fortress Biotech subsidiary gains FDA approval for cSCC therapy By Investing.com - Investing.com UK
Objective long/short (FBIOP) Report - Stock Traders Daily
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire
Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan
Fortress Biotech (FRA:CNB1) EV-to-Revenue : 0.52 (As of Dec. 04, 2024) - GuruFocus.com
Biotech Stocks Facing FDA Decision In December 2024 - RTTNews
Fortress Biotech (STU:CNB1) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
Fortress Biotech (STU:CNB1) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Loungers accepts £340m takeover by Fortress - Verdict Foodservice
Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP - Defense World
FBIOP.PFD (Fortress Biotech) Earnings Yield % : N/A% (As of Nov. 23, 2024) - GuruFocus.com
(FBIOP) Trading Signals - Stock Traders Daily
Fortress Biotech (FRA:CNB0.PFD) Total Liabilities : €125.98 Mil (As of Sep. 2024) - GuruFocus.com
Certain Restricted Stock Units of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Fortress Biotech (FRA:CNB1) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024) - GuruFocus.com
Fortress Biotech price target raised to $15 from $13 at Roth MKM - TipRanks
Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks
Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fortress Biotech: Q3 Earnings Snapshot - mySA
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks
Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Fortress Biotech Inc (FBIO) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):